Physician profile
Kyle H Kindley
NPI 1902149784
$857.25
in general payments reported to CMS, 2019-2025
15 companies · $438 in 2025
The $438 reported for 2025 was more than what 92% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $64.94 · 2024: $354 · 2025: $438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $857.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $192.58 | 2024-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $177.37 | 2024 | Omnipod |
| Pfizer INC. | $130.66 | 2023-2025 | |
| Ani Pharmaceuticals, INC. | $55.76 | 2025 | Purified Cortrophin Gel |
| Abbvie INC. | $53.16 | 2023-2025 | |
| Corcept Therapeutics | $40.46 | 2025 | Korlym |
| Novo Nordisk INC | $33.17 | 2023-2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.55 | 2024-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.38 | 2024-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $27.06 | 2024 | Farxiga, Airsupra |
| Exact Sciences Corporation | $21.14 | 2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $18.91 | 2025 | Voquezna |
| Abbott Laboratories | $18.41 | 2025 | Freestyle Libre 3 |
| Amgen INC. | $14.44 | 2024 | Repatha, Otezla |
| Lundbeck LLC | $13.20 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Kindley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.